RMD Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

219.980

Open

219.340

VWAP

218.75

Vol

1.73M

Mkt Cap

31.88B

Low

216.520

Amount

377.64M

EV/EBITDA(TTM)

14.33

Total Shares

145.06M

30.68B

EV/OCF(TTM)

16.24

P/S(TTM)

5.78

ResMed Inc. is a holding company. The Company, through its subsidiaries, in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. Its segments include Sleep and Breathing Health segment and the Residential Care Software segment. It also operates a Software as a Service (SaaS) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. Its products and solutions are designed to improve patients' quality of life and reduce the impact of chronic disease. Its cloud-based digital health software applications, along with its devices, are designed to provide connected care.

Events Timeline

(ET)

2026-07-07

17:30:00

Frazier Healthcare Partners to Acquire MatrixCare

2026-07-07

17:00:00

Resmed Sells MatrixCare Business to Frazier Healthcare Partners

2026-06-17 (ET)

2026-06-17

16:30:00

Federal Reserve Keeps Rates Unchanged, Markets Close Lower

2026-06-17

12:00:00

Major Averages Slightly Higher as Markets Await Fed Meeting

News

8.5

07-07Newsfilter

PinnedResmed Sells MatrixCare Business to Frazier Healthcare Partners

8.5

07-07seekingalpha

Frazier Healthcare Partners to Acquire MatrixCare from Resmed

7.5

07-07seekingalpha

Resmed Sells MatrixCare to Focus on Core Healthcare

2.0

07-03Yahoo Finance

ResMed Stock Rises After Goldman Sachs Inclusion

9.5

07-02NASDAQ.COM

ResMed Announces Q3 2026 Financial Results and Upcoming Webcast

6.5

07-01NASDAQ.COM

ResMed Stock Price Potential Analysis

11 Analyst Rating

Wall Street analysts forecast RMD stock price to rise

6 Buy

5 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

260.00

Averages

294.00

High

345.00

Current: 0.000

Low

260.00

Averages

294.00

High

345.00

Goldman Sachs

Buy

maintain

$46.70

AI Analysis

2026-07-01

Reason

Goldman Sachs

Price Target

$46.70

AI Analysis

2026-07-01

maintain

Buy

Reason

Goldman Sachs analysts added ResMed to the firm's APAC Conviction List as part of its monthly update. The firm expects continuous airway pressure therapy patient growth for the company. It keeps a Buy rating on the shares with a A$46.70 price target.

KeyBanc

Overweight

downgrade

$290 -> $266

2026-06-22

Reason

KeyBanc

Price Target

$290 -> $266

2026-06-22

downgrade

Overweight

Reason

KeyBanc lowered the firm's price target on ResMed to $266 from $290 and keeps an Overweight rating on the shares. Last week's attendance at the SLEEP APSS Meeting in Baltimore and additional diligence on the OSA competitive landscape reinforced a positive view of underlying OSA/CPAP patient activity, with continued enthusiasm around demand growth driven by GLP-1s and consumer wearables, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RMD

Unlock Now

Valuation Metrics

The current forward P/E ratio for Resmed Inc (RMD.N) is 17.67, compared to its 5-year average forward P/E of 27.47. For a more detailed relative valuation and DCF analysis to assess Resmed Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

27.47

Current PE

17.67

Overvalued PE

36.88

Undervalued PE

18.06

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

20.76

Current EV/EBITDA

12.25

Overvalued EV/EBITDA

26.18

Undervalued EV/EBITDA

15.35

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

7.06

Current PS

4.99

Overvalued PS

8.65

Undervalued PS

5.47

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

Show US

Intellectia · 35 candidates

Market Cap: >= 10.00BRegion: USBeta: ModerateRiskPe Ttm: 5 - 30Return On Equity: >= 10.0%Is Index Component: GSPC, NDX

Ticker

Name

Market Cap$

MSFT

Microsoft Corp

3.10T

Home Depot Inc

349.60B

Goldman Sachs Group Inc

277.81B

AXP

American Express Co

226.22B

ADBE

Adobe Inc

100.50B

PNC

PNC Financial Services Group Inc

91.28B

추천해준 38개 주식중에서 가장 상승확률이 높은 주식3개로 정리해줘

Intellectia · 14 candidates

Market Cap: >= 5.00BRegion: USList Exchange: XNYS, XNASOne Day Rise Prob: >= 90One Day Predict Return: 1.0% - 5.0%Monthly Average Dollar Volume: >= 20,000,000

Ticker

Name

Market Cap$

FLEX

Flex Ltd

22.27B

VIST

Vista Energy SAB de CV

7.98B

VIAV

Viavi Solutions Inc

7.36B

WEX

WEX Inc

5.26B

LECO

Lincoln Electric Holdings Inc

13.39B

SRE

Sempra

63.10B

what stock should I buy

Intellectia · 91 candidates

Region: USAnalyst Consensus: Strong Buy, Moderate BuyRevenue 5yr Cagr: >= 8Pe Ttm: 10 - 35List Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePrice, AbovePriceIs Index Component: GSPC

Ticker

Name

Market Cap$

AMZN

Amazon.com Inc

2.20T

HST

Host Hotels & Resorts Inc

12.79B

UBER

Uber Technologies Inc

152.07B

General Motors Co

65.82B

RSG

Republic Services Inc

67.72B

LVS

Las Vegas Sands Corp

35.56B

Which stock is best for investing $500

Intellectia · 65 candidates

Market Cap: >= 10.00BRegion: USPrice: $10.00 - $300.00Analyst Consensus: Strong Buy, Moderate BuyRevenue 5yr Cagr: >= 0Eps 5yr Cagr: >= 0Pe Ttm: 10 - 30Return On Equity: >= 10.0%Is Index Component: GSPCAnnual Eps Yoy Growth: >= 0.0%

Ticker

Name

Market Cap$

CTRA

Coterra Energy Inc

23.90B

OKE

ONEOK Inc

54.24B

VICI

VICI Properties Inc

32.45B

Morgan Stanley

265.17B

SCHW

Charles Schwab Corp

167.32B

PGR

Progressive Corp

125.08B

which stocks should I buy right now

Intellectia · 45 candidates

Rsi Category: moderateRevenue 5yr Cagr: >= 5Pe Ttm: 10 - 30Moving Average Relationship: PriceAboveMA20Is Index Component: GSPCOne Month Predict Return: >= 0.0%

Ticker

Name

Market Cap$

DRI

Darden Restaurants Inc

24.67B

AWK

American Water Works Co Inc

25.95B

NRG

NRG Energy Inc

38.11B

SNA

Snap-On Inc

20.01B

HAL

Halliburton Co

29.52B

COP

ConocoPhillips

134.31B

good long term investments

Intellectia · 40 candidates

Market Cap: >= 30.00BRegion: USNet Margin: >= 10.00Revenue 5yr Cagr: >= 8Pe Ttm: 10 - 30List Exchange: XNYS, XNAS, XASEReturn On Equity: >= 15.0%

Ticker

Name

Market Cap$

LVS

Las Vegas Sands Corp

38.98B

LNG

Cheniere Energy Inc

48.74B

TRGP

Targa Resources Corp

49.73B

NVO

Novo Nordisk A/S

211.73B

AMP

Ameriprise Financial Inc

43.01B

ADBE

Adobe Inc

106.16B

what do I buy?

Intellectia · 80 candidates

Quarter Revenue Yoy Growth: >= 5.0%Net Margin: >= 10.00Beta: LowRisk, ModerateRiskPe Ttm: 10 - 30List Exchange: XNYS, XNAS, XASEIs Index Component: GSPC

Ticker

Name

Market Cap$

VRSN

VeriSign, Inc

19.80B

SPG

Simon Property Group Inc

65.81B

AMP

Ameriprise Financial Inc

43.01B

PNC

PNC Financial Services Group Inc

94.19B

CME

CME Group Inc

111.10B

ICE

Intercontinental Exchange Inc

87.46B

<$2 stock or cryptocurrency to buy now

Intellectia · 31 candidates

Region: USAnalyst Consensus: Strong Buy, Moderate BuyPe Ttm: 8 - 35Moving Average Relationship: PriceAboveMA20Is Index Component: GSPC, NDXAnnual Revenue Yoy Growth: >= 8.0%One Month Predict Return: >= 0.0%

Ticker

Name

Market Cap$

WDC

Western Digital Corp

87.21B

AZN

AstraZeneca PLC

290.26B

GOOG

Alphabet Inc

4.03T

MPWR

Monolithic Power Systems Inc

53.41B

WYNN

Wynn Resorts Ltd

11.94B

Bank of New York Mellon Corp

83.68B

pick 10 stocks to out perform the s&p 500

Intellectia · 33 candidates

Market Cap: >= 2.00BAnalyst Consensus: Strong Buy, Moderate BuyRevenue 5yr Cagr: >= 10Eps 5yr Cagr: >= 10Return On Equity: >= 15.0%Target Price Upside Potential: AbovePriceOne Month Predict Return: >= 0.0%

Ticker

Name

Market Cap$

AMZN

Amazon.com Inc

2.54T

HLNE

Hamilton Lane Inc

7.50B

CWAN

Clearwater Analytics Holdings Inc

6.97B

CMG

Chipotle Mexican Grill Inc

50.86B

Visa Inc

633.82B

Axos Financial Inc

5.50B

best stock right now to buy

Intellectia · 19 candidates

Market Cap: >= 10.00BRegion: USRevenue 5yr Cagr: >= 10Pe Ttm: 10 - 30List Exchange: XNYS, XNAS, XASEReturn On Equity: >= 15.0%Moving Average Relationship: PriceAboveMA20

Ticker

Name

Market Cap$

NVO

Novo Nordisk A/S

263.91B

LNG

Cheniere Energy Inc

45.53B

MPWR

Monolithic Power Systems Inc

53.85B

TRGP

Targa Resources Corp

43.14B

AMP

Ameriprise Financial Inc

48.13B

RCL

Royal Caribbean Cruises Ltd

87.79B

Whales Holding RMD

Bellevue Asset Management AG

American Capital Management, Inc.

Blackhill Capital, Inc

Triodos Investment Management B.V.

BetaShares Capital Limited

BLI - Banque De Luxembourg Investments S.A.

Trading Trends

People Also Watch

Frequently Asked Questions

What is Resmed Inc (RMD) stock price today?

The current price of RMD is 219.75 USD — it has increased 0.62

What is Resmed Inc (RMD)'s business?

What is the price predicton of RMD Stock?

Wall Street analysts forecast RMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RMD is294.00 USD with a low forecast of 260.00 USD and a high forecast of 345.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.